Compare BAER & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BAER | MDXH |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.3M | 183.4M |
| IPO Year | N/A | 2021 |
| Metric | BAER | MDXH |
|---|---|---|
| Price | $2.68 | $3.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.25 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 1.1M | 132.5K |
| Earning Date | 03-12-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $129,868,000.00 | $103,069,000.00 |
| Revenue This Year | $24.95 | $23.34 |
| Revenue Next Year | $10.18 | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 54.35 | 21.68 |
| 52 Week Low | $1.02 | $1.35 |
| 52 Week High | $3.44 | $5.33 |
| Indicator | BAER | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 46.17 |
| Support Level | $2.68 | $3.45 |
| Resistance Level | $3.03 | $3.80 |
| Average True Range (ATR) | 0.31 | 0.20 |
| MACD | -0.06 | -0.02 |
| Stochastic Oscillator | 22.21 | 12.96 |
Bridger Aerospace Group Holdings Inc operates as an aerial firefighting company. It provides aerial wildfire surveillance, relief and suppression, and aerial firefighting services using next-generation technology and environmentally friendly and sustainable firefighting methods. Bridger Aerospace provides aerial firefighting and wildfire management services to federal and state government agencies, including the United States Forest Service, across the nation. The company's portfolio is organized across two offerings: Fire Suppression, which Consists of deploying specialized Viking CL-415EAF (Super Scooper) aircraft to drop large amounts of water quickly and directly on wildfires, and Aerial Surveillance, providing aerial surveillance via manned aircraft for fire suppression aircraft.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.